Jeppe Øvlesen
Directeur Général chez SYNACT PHARMA AB
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Thomas Jonassen | M | - |
Action Pharma A/S
 Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis.
ResoTher Pharma AS
 ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | - |
| Ole Kjerkegaard Nielsen | M | - |
Go-PEN Aps
 Go-PEN Aps Medical SpecialtiesHealth Technology Go-Pen ApS develops insulin pen. The Danish company was founded in 2019 by Ole Kjerkegaard Nielsen, Michael Ejstrup Hansen. Ole Kjerkegaard Nielsen has been the CEO since 2019. | 5 ans |
| Kim Beuschau Mouridsen | M | - |
Cercare Medical A/S
 Cercare Medical A/S Packaged SoftwareTechnology Services Cercare Medical ApS provides automated identification of viable tissue in acute stroke. It develops technology within medical image processing and image database analytics. The firm creates diagnostic software. The company was founded by Kim Mouridsen and Mikkel Bo Hansen in October 2013 and is headquartered in Aarhus, Denmark. | 11 ans |
| Henrik Stage | M | - |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | 7 ans |
| Gunnar Olof Olsson | M | 71 | - | |
| Michael Hansen | M | - |
Go-PEN Aps
Go-PEN Aps Medical SpecialtiesHealth Technology Go-Pen ApS develops insulin pen. The Danish company was founded in 2019 by Ole Kjerkegaard Nielsen, Michael Ejstrup Hansen. Ole Kjerkegaard Nielsen has been the CEO since 2019. | 5 ans |
| Claes Sverker Jern | M | 70 | 12 ans | |
| Björn Lennart Dahlöf | M | 71 | 12 ans | |
| Jonas Per Åke Faijerson Säljö | M | 47 | 12 ans | |
| Habib Frost | M | - |
Neurescue ApS
 Neurescue ApS Medical SpecialtiesHealth Technology Neurescue ApS develops innovative medical devices for the treatment of cardiac arrest. It offers new platform of treatment methods for paramedics, nurses and doctors alike. The company was founded by Habib Frost in 2013 and is headquartered in Copenhagen, Denmark. | 11 ans |
| Mikkel Bo Hansen | M | - |
Cercare Medical A/S
Cercare Medical A/S Packaged SoftwareTechnology Services Cercare Medical ApS provides automated identification of viable tissue in acute stroke. It develops technology within medical image processing and image database analytics. The firm creates diagnostic software. The company was founded by Kim Mouridsen and Mikkel Bo Hansen in October 2013 and is headquartered in Aarhus, Denmark. | 11 ans |
| Thomas Boesen | M | - |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | 3 ans |
| Aitana Peire | M | - |
Cercare Medical A/S
Cercare Medical A/S Packaged SoftwareTechnology Services Cercare Medical ApS provides automated identification of viable tissue in acute stroke. It develops technology within medical image processing and image database analytics. The firm creates diagnostic software. The company was founded by Kim Mouridsen and Mikkel Bo Hansen in October 2013 and is headquartered in Aarhus, Denmark. | - |
| Eva Jagenheim | F | 58 | 1 ans | |
| Mette-Marie Harild | F | 66 |
Neurescue ApS
Neurescue ApS Medical SpecialtiesHealth Technology Neurescue ApS develops innovative medical devices for the treatment of cardiac arrest. It offers new platform of treatment methods for paramedics, nurses and doctors alike. The company was founded by Habib Frost in 2013 and is headquartered in Copenhagen, Denmark. | 3 ans |
| Tiina Seppä | M | 53 | - | |
| Fredrik Frick | M | 51 | 2 ans | |
| Etienne Adriansen | M | 60 | 1 ans | |
| Anders Svensson | M | 73 | 6 ans | |
| Michael Holinstat | M | 52 | 3 ans | |
| Jan-Peter Idström | M | 68 | 7 ans | |
| Elin Segetorp | F | 46 | - | |
| Joakim Söderström | M | 40 | 1 ans | |
| Niels Jesper Jensen | M | - |
CPHI-Holding A/S
 CPHI-Holding A/S Miscellaneous Commercial ServicesCommercial Services CPHI-Holding A/S is a Danish company based in Rodovre, Denmark. The CEOs are Michael Østerlund Madsen, Peter Scheuer Jensen. CPHI-Holding develops airport solutions to enhance passenger experience, including security scanner systems, intelligent trolleys, and baggage handling technologies. The private company has a team of over 30 employees. The company was founded in 1999 by Lars Hojgaard Thogersen, Søren Jakobsen, Rasmus Halfdan Breck. | 8 ans |
| Thani Abdulla Alzaffin | M | - |
CPHI-Holding A/S
CPHI-Holding A/S Miscellaneous Commercial ServicesCommercial Services CPHI-Holding A/S is a Danish company based in Rodovre, Denmark. The CEOs are Michael Østerlund Madsen, Peter Scheuer Jensen. CPHI-Holding develops airport solutions to enhance passenger experience, including security scanner systems, intelligent trolleys, and baggage handling technologies. The private company has a team of over 30 employees. The company was founded in 1999 by Lars Hojgaard Thogersen, Søren Jakobsen, Rasmus Halfdan Breck. | 8 ans |
| Ole Vahlgren | M | 61 |
Go-PEN Aps
Go-PEN Aps Medical SpecialtiesHealth Technology Go-Pen ApS develops insulin pen. The Danish company was founded in 2019 by Ole Kjerkegaard Nielsen, Michael Ejstrup Hansen. Ole Kjerkegaard Nielsen has been the CEO since 2019. | - |
| Flemming Møller | M | - |
Neurescue ApS
Neurescue ApS Medical SpecialtiesHealth Technology Neurescue ApS develops innovative medical devices for the treatment of cardiac arrest. It offers new platform of treatment methods for paramedics, nurses and doctors alike. The company was founded by Habib Frost in 2013 and is headquartered in Copenhagen, Denmark. | - |
| Henrik Kähler | M | - |
Go-PEN Aps
Go-PEN Aps Medical SpecialtiesHealth Technology Go-Pen ApS develops insulin pen. The Danish company was founded in 2019 by Ole Kjerkegaard Nielsen, Michael Ejstrup Hansen. Ole Kjerkegaard Nielsen has been the CEO since 2019. | - |
| Lena Mårtensson | M | 70 | 2 ans | |
| Sten Randahl Sörensen | M | 65 | 9 ans | |
| Björn Westberg | M | 62 | 1 ans | |
| Oliver Johansen | M | 53 |
Neurescue ApS
Neurescue ApS Medical SpecialtiesHealth Technology Neurescue ApS develops innovative medical devices for the treatment of cardiac arrest. It offers new platform of treatment methods for paramedics, nurses and doctors alike. The company was founded by Habib Frost in 2013 and is headquartered in Copenhagen, Denmark. | - |
| James Knight | M | - | 3 ans | |
| Susanne Hauschildt Bendz | M | 66 |
Neurescue ApS
Neurescue ApS Medical SpecialtiesHealth Technology Neurescue ApS develops innovative medical devices for the treatment of cardiac arrest. It offers new platform of treatment methods for paramedics, nurses and doctors alike. The company was founded by Habib Frost in 2013 and is headquartered in Copenhagen, Denmark. | - |
| Niels Erik Nielsen | M | 76 |
CPHI-Holding A/S
CPHI-Holding A/S Miscellaneous Commercial ServicesCommercial Services CPHI-Holding A/S is a Danish company based in Rodovre, Denmark. The CEOs are Michael Østerlund Madsen, Peter Scheuer Jensen. CPHI-Holding develops airport solutions to enhance passenger experience, including security scanner systems, intelligent trolleys, and baggage handling technologies. The private company has a team of over 30 employees. The company was founded in 1999 by Lars Hojgaard Thogersen, Søren Jakobsen, Rasmus Halfdan Breck. | 6 ans |
| Jesper Andreasen | M | - |
CPHI-Holding A/S
CPHI-Holding A/S Miscellaneous Commercial ServicesCommercial Services CPHI-Holding A/S is a Danish company based in Rodovre, Denmark. The CEOs are Michael Østerlund Madsen, Peter Scheuer Jensen. CPHI-Holding develops airport solutions to enhance passenger experience, including security scanner systems, intelligent trolleys, and baggage handling technologies. The private company has a team of over 30 employees. The company was founded in 1999 by Lars Hojgaard Thogersen, Søren Jakobsen, Rasmus Halfdan Breck. | 6 ans |
| Sven M. Jacobson | M | - |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | - |
| Thomas Feldthus | M | 64 |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | - |
| Finn W. Andersen | M | - |
Neurescue ApS
Neurescue ApS Medical SpecialtiesHealth Technology Neurescue ApS develops innovative medical devices for the treatment of cardiac arrest. It offers new platform of treatment methods for paramedics, nurses and doctors alike. The company was founded by Habib Frost in 2013 and is headquartered in Copenhagen, Denmark. | - |
| Anders Kronborg | M | 60 |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | 1 ans |
| Kirsten Drejer | M | 68 |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | - |
| Ulrik Spork | M | - |
Neurescue ApS
Neurescue ApS Medical SpecialtiesHealth Technology Neurescue ApS develops innovative medical devices for the treatment of cardiac arrest. It offers new platform of treatment methods for paramedics, nurses and doctors alike. The company was founded by Habib Frost in 2013 and is headquartered in Copenhagen, Denmark. | - |
| Kirsten Harting | M | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Torbjørn Bjerke | M | 61 |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | 8 ans |
| Uli Alf Hacksell | M | 74 | - | |
| Patrik Renblad | M | 54 | 2 ans | |
| Lene Gerlach | M | - |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | - |
| Frank Armstrong | M | 67 |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | 6 ans |
| Anders Dyhr Toft | M | - | 1 ans | |
| Kerstin Hasselgren | F | 63 | 2 ans | |
| Thierry Duvauchelle | M | - | - | |
| Benedikt Fraitzl | M | - |
NordEnergie Renewables A/S
 NordEnergie Renewables A/S Electric UtilitiesUtilities NordEnergie Renewables A/S is a holding company that supplies households with pure and renewable energy. It is an independent power producer of wind power, an alternative to the traditional ways of generating energy. The firm owns and operates wind parks situated in Germany and Sweden. The company was founded in November 2007 and is headquartered in Copenhagen, Denmark. | - |
| Nils Thomas von Koch | M | 58 | 1 ans | |
| Jón Ingi Benediktsson | M | - |
Cercare Medical A/S
Cercare Medical A/S Packaged SoftwareTechnology Services Cercare Medical ApS provides automated identification of viable tissue in acute stroke. It develops technology within medical image processing and image database analytics. The firm creates diagnostic software. The company was founded by Kim Mouridsen and Mikkel Bo Hansen in October 2013 and is headquartered in Aarhus, Denmark. | - |
| Marina Bozilenko | F | 59 | 3 ans | |
| Preben Edvard Kønig | M | 74 | - | |
| Thomas Knudsen | M | 54 |
Vintage Cloud A/S
 Vintage Cloud A/S Electronics DistributorsDistribution Services Vintage Cloud ApS engages in the wholesale of computers, peripherals, and software. The firm’s purpose is the development and sale of archive systems and related activities. The company was founded on February 21, 2012 and is headquartered in Copenhagen, Denmark. | 1 ans |
| Jorgen Frokiaer | M | - |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | - |
| John Sørensen Haurum | M | 61 | - | |
| Charlotte Elisabet Edenius | M | 66 | - | |
| Terje Kalland | M | 73 | 5 ans | |
| Lars Ivar Robert Adlersson | M | 60 | - | |
| Lone Veng | M | - |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Danemark | 34 | 53,97% |
| Suède | 33 | 52,38% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jeppe Øvlesen
- Réseau Personnel
